Rapid decrease of wild-type hepatitis C virus on telaprevir treatment

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 591-595

  Adiwijaya, Bambang S ^a   Hare, Brian ^a   Caron, Paul R ^a   Randle, John C R ^a,b   Neumann, Avidan U ^c   Reesink, Hendrik W ^d   Zeuzem, Stefan ^e   Herrmann, Eva ^e  

^a VERTEX PHARMACEUTICALS   (United States)

^b Horizon CombinatoRx   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CILUPREVIR; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; POLYETHYLENE GLYCOL INTERFERON BETA 1A; POLYETHYLENE GLYCOL-INTERFERON BETA-1A;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS LOAD; VIRUS TYPING; WILD TYPE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; PHASE 1 CLINICAL TRIAL;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS;

EID: 68549092559     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Purcell RH. Hepatitis C virus: historical perspective and current concepts. FEMS Microbiol Rev 1994; 14:181-192.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med 2002; 347:975-982.
3. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24:97-104.
4. Reesink FIW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002.
5. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640-648.
6. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamic in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
7. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a. Gastroenterology 2001; 120:1438-1447.
8. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
9. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432:922-924.
10. Herrmann E, Zeuzcm S, Sarrazin C, et al. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther 2006; 11:371-376.
11. Neumann AU, Rozenberg L, Reesink HW, Zeuzem S, Chu HM. Novel mode of viral decline during telaprevir (VX-950) and PEG-IFN combination treatment predicted by a new combined intracellular and cellular hepatitis C viral dynamics model. J Hepatol 2007; 46 Suppi 1:S236.
12. Kieffer TL, Sarrazin C Miller J, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 HCV replication in patients, Hepatology 2007; 46:631-639.
13. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alfa-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-1278.
14. Ralston R. Development of resistance to boceprevir: observations from clinical trials, 2nd International Workshop on Hepatitis C Resistance and New Compounds. 31 October-1 November 2008, Boston, MA. USA.
15. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46:16-21.
16. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-1350.
17. Kronenberger B, Herrmann E, Micol F, Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40:1442-1449.
18. Pirie W. Jonckheere tests for ordered alternatives. In Kotz S, Johnson NL, Read CB (Editors). Encyclopedia of statistical sciences. Vol. 4. New York: Wiley 1983; pp. 315-318.
19. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-1148.
20. Li K, Foy E, Ferreon JC, et al. Immune evasion by hephtitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997.
21. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36:s145-s151.